SillaJen, Inc. (KOSDAQ:215600)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,585.00
-50.00 (-1.38%)
Apr 28, 2026, 3:30 PM KST
-6.88%
Market Cap 495.20B
Revenue (ttm) 9.23B
Net Income (ttm) -24.19B
Shares Out 138.13M
EPS (ttm) -175.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 800,879
Average Volume 1,210,159
Open 3,635.00
Previous Close 3,635.00
Day's Range 3,570.00 - 3,645.00
52-Week Range 2,650.00 - 5,400.00
Beta 0.11
RSI 43.70
Earnings Date Mar 20, 2026

About SillaJen

SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 57
Stock Exchange KOSDAQ
Ticker Symbol 215600
Full Company Profile

Financial Performance

In 2025, SillaJen's revenue was 9.23 billion, an increase of 134.94% compared to the previous year's 3.93 billion. Losses were -24.19 billion, -8.81% less than in 2024.

Financial Statements

News

There is no news available yet.